Morgan Stanley analyst Michael E. Ulz upgraded Arrowhead Pharma (NASDAQ: ARWR) from Equalweight to Overweight with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades